The traditional, batch-oriented approach to clinical trial data collection and analysis is undergoing a seismic shift with the advent of Real-Time Clinical Trials (RTCT). While this innovation promises to accelerate drug development and bring life-saving therapies to patients faster, it presents a significant, often overlooked, challenge: the urgent need to modernize clinical supply chains. Meghna Rajesh, Senior Research Analyst at Beroe Inc., argues that sponsors must proactively address these supply chain implications now to fully harness the potential of RTCT.
For nearly six decades, the fundamental framework of drug development has remained largely static. Patient data is meticulously collected at clinical sites, then aggregated, cleaned, and analyzed by sponsors in periodic batches. Regulatory bodies typically receive these findings in substantial reports, often months after the critical events they describe. This inherent lag has been a persistent bottleneck, leading to prolonged development timelines and delayed patient access to potentially groundbreaking treatments.
The urgency of this issue was underscored by former FDA Commissioner Marty Makary when the agency officially announced its Real-Time Clinical Trials (RTCT) initiative on April 28, 2026. "For 60 years, we’ve been conducting clinical trials the same way, where key data signals can take years to reach the FDA," Makary stated, highlighting the critical need for a more agile and responsive system.
The Dawn of Real-Time Data: Closing the Information Gap
RTCT is designed precisely to bridge this information chasm. The core principle involves the pre-agreed transmission of crucial safety signals and efficacy endpoints directly from sponsor platforms to FDA reviewers while the trial is still actively in progress, rather than waiting for a complete database lock. This fundamental change has the potential to dramatically shorten decision-making cycles and streamline the entire drug development process.
The transformative potential of RTCT is already being explored through two live proof-of-concept studies. The first is AstraZeneca’s TRAVERSE, a Phase II study investigating treatment-naïve mantle cell lymphoma at MD Anderson and the University of Pennsylvania. The second is Amgen’s Phase Ib STREAM-SCLC study, focusing on limited-stage small cell lung cancer. Paradigm Health, whose platform played a pivotal role in validating the signals within the AstraZeneca study, reported that key data can now be shared "with trial sponsors and the FDA in days, rather than months," as initially reported by Clinical Trials Arena at the initiative’s launch.
The FDA’s long-term vision extends beyond these initial pilots to what it terms "continuous trials." In this model, the traditional pauses between Phase I, II, and III trials could be significantly reduced or even eliminated. This is predicated on regulators having immediate access to the necessary evidence to make informed go/no-go decisions at each stage, fostering an unprecedented level of efficiency.
Beyond the Data: The Unseen Impact on Clinical Supply Chains
While the discourse surrounding RTCT has largely centered on its implications for regulators, biostatisticians, and data managers, a crucial stakeholder group poised to experience its impact just as acutely has received far less attention: the individuals responsible for procuring and managing the vast array of resources that keep a clinical trial operational. As decision-making accelerates, the clinical supply chain must evolve in tandem. However, the majority of existing supplier contracts were not designed with this newfound agility in mind.
From Batch Processing to Real-Time Streams: Why Procurement Must Take Notice
In conventional clinical trials, data flows in a linear fashion: from site visits and monitor collections to Electronic Data Capture (EDC) entry, data cleaning, database lock, and scheduled submissions. Each of these sequential steps introduces inherent delays. These lags have quietly shaped procurement practices. Demand forecasts are typically generated based on historical enrollment rates and protocol assumptions, with subsequent adjustments made upon receiving Interactive Response Technology (IRT) reports. Manufacturing slots are secured months in advance for pre-determined volumes, and supplier performance is evaluated on a monthly or quarterly basis. The cadence of procurement activities has, by necessity, mirrored the rhythm of reporting.
RTCT fundamentally disrupts this established rhythm. If regulatory review reveals a clear safety profile by week six of a Phase I study, a sponsor might be compelled to advance to Phase II much sooner than their initial supply plan anticipated. Conversely, if an adverse signal emerges at week ten, active manufacturing may need to be halted within days. In either scenario, the costly consequence remains the same: a supply chain operating on outdated forecasts from the previous quarter, while the trial itself has already moved forward.
This dynamic elevates RTCT from a purely regulatory concern to a significant procurement imperative. The impact will be felt most acutely across five key areas of supply chain management.
Forecasting Must Look Forward, Not Back: Embracing Predictive Demand
Historically, clinical supply has incorporated substantial safety margins due to the inherent uncertainties in forecasting. Sponsors commonly plan for 150% to 200% overage to account for unpredictable enrollment rates, patient attrition, and country-specific variations, according to data from ZS. IQVIA further estimates that the median waste of investigational product kits across trials hovers around 50%. A significant portion of this buffer exists primarily because sponsors receive real-time demand insights too late in the process.
The integration of live enrollment and visit-completion data fundamentally alters this equation. When the same signals that inform the FDA also reach the supply chain team, demand can be predicted weeks in advance, rather than being reactively reconstructed after a shortfall occurs. The practical implementation of this shift necessitates contractual adjustments. IRT agreements should mandate that real-time demand signals are made accessible via an Application Programming Interface (API) to the sponsor’s planning and procurement systems, extending beyond the clinical team’s dashboard. Without such a clause, the data may exist, but the individuals responsible for ordering supplies will not receive it in a timely manner. Even a modest reduction in overage for a large-scale program can yield significant budget savings, making this a readily justifiable aspect of the RTCT business case internally.
It is crucial to emphasize that real-time data does not eliminate the need for buffer stock; treating it as such would be a misstep. Manufacturing lead times, release testing protocols, and import timelines do not magically shorten simply because data transmission is faster. What does change is the optimal location and redeployment speed of this buffer. A sponsor equipped with live visibility can maintain safety stock centrally and efficiently distribute it to sites requiring it, rather than spreading it uniformly across all depots in anticipation of unforeseen demands.
CDMO Contracts Need Inherent Flexibility, Not Post-Negotiation Additions
Fixed-volume, fixed-schedule manufacturing agreements are in place for valid reasons. They secure essential capacity for sponsors and provide Contract Development and Manufacturing Organizations (CDMOs) with predictable revenue streams. However, under the RTCT framework, these rigid structures can become a significant liability.
Phase transitions that once spanned months could now compress into mere weeks. The critical question then becomes: what happens when the trial’s trajectory changes, but the contract remains static? The sponsor is forced to renegotiate, effectively negating the time savings achieved through RTCT on the regulatory front by introducing delays in manufacturing.
The solution lies in embedding flexibility directly into the sourcing stage. This involves designing scale-up triggers tied to specific enrollment thresholds, incorporating scale-down or pause rights without imposing punitive penalties, and establishing options to advance or defer production milestones. This same principle extends to comparator sourcing and cold-chain logistics, where replenishment can be synchronized with actual site consumption rather than adhering to a fixed calendar.
Consider a first-in-human oncology study with a single drug product campaign sized for dose escalation. If safety data supports the early opening of an expansion cohort, a CDMO agreement with a reserved slot that can be confirmed based on an enrollment trigger allows the sponsor to simply exercise an option. Without such a clause, the sponsor faces the prospect of joining a waiting list.
Will CDMOs impose charges for this inherent flexibility? Naturally, and rightly so. The negotiation shifts from a focus on unit price to the cost of optionality. Sponsors capable of sharing reliable real-time demand data will be in the strongest position to negotiate these costs down.
Participant Support Must Mirror Data Velocity
Stipends disbursed bi-weekly, travel arrangements made days in advance, and reimbursements processed in batches – this remains the prevailing norm in most clinical trials. When visit status is reported in near real-time, it raises the question: why should financial support lag behind? Patients will undoubtedly pose this question, and sponsors must be prepared with a satisfactory answer. Linking stipends and reimbursements to confirmed visit completion is a straightforward adjustment. Patient payment and travel vendors should be assessed for their capability to automate these triggers.
Patient retention is one of the most fragile components of any clinical trial. Its importance is amplified when regulators are actively monitoring dropout rates in real-time. Ensuring that participant support systems can keep pace with the flow of data is paramount to maintaining trial integrity and patient engagement.
Vendor Qualification Undergoes a Real-Time Scrutiny
Many of the systems integral to clinical trials, from eCOA and IRT to patient payment platforms, were originally architected for scheduled file exports. RTCT, however, favors platforms that facilitate continuous data exchange through secure, well-documented APIs.
While the FDA has yet to release detailed technical specifications for real-time reporting, this absence of immediate guidance should serve as a catalyst for preparation, not a reason for inaction. Four critical questions should be incorporated into Requests for Proposals (RFPs) from this point forward:
- Does the platform support event-driven data exchange via APIs?
- What data latency will the vendor commit to within its Service Level Agreement (SLA)?
- How are audit trails and 21 CFR Part 11 controls maintained for streamed data?
- Can the platform integrate with the sponsor’s RTCT platform without requiring a custom build?
A vendor unable to provide affirmative answers to all four questions today may not be immediately disqualified. However, their development roadmap should be thoroughly evaluated, and their commitments meticulously documented within the contract.
Furthermore, oversight methodologies must evolve. Monthly performance reviews become increasingly anachronistic for a trial that generates daily reports. Real-time dashboards and automated alerts, monitored against key performance indicators (KPIs) such as forecast accuracy, the time elapsed from demand signal to resupply, and data latency, will offer a far more insightful assessment of readiness than traditional metrics like cost per kit.
A New Category of Expenditure: The Real-Time Data Pipeline
RTCT introduces a novel requirement that procurement professionals have historically not had to address: the acquisition and management of the pipeline responsible for transmitting trial data to regulatory bodies. Reports from Clinical Trials Arena indicate that Paradigm Health’s end-to-end trial platform is being utilized across the RTCT program through a collaborative arrangement with the FDA.
This development gives rise to a series of questions that fall squarely within the purview of procurement. Who will hold the contract for this critical infrastructure – the sponsor or the Contract Research Organization (CRO)? Who will bear the costs associated with integration and validation? And critically, who will retain ownership of the connection to the regulator should the CRO relationship terminate midway through a study?
Full-service CROs may offer to manage this complex layer as part of their service package. While convenient, this approach can create significant hurdles for switching providers at a later stage. Conversely, sourcing the technology directly grants greater control but necessitates assuming the full burden of integration. Neither model is universally applicable to every sponsor. The paramount consideration is making a deliberate choice rather than passively inheriting a solution from whichever vendor happens to be involved in the initial RTCT deployments.
One contractual clause warrants particular attention: data access. Who is granted permission to view streamed data, in what format, and at what intervals? And crucially, who is held accountable in the event of a transmission error reaching the FDA? The vast majority of current eClinical contracts remain silent on both these critical aspects.
Mitigating Risks: Procurement’s Crucial Role in Containment
The advent of real-time visibility presents a dual-edged sword. As highlighted by Kimberly Chew and Odette Hauke in Clinical Leader, the potential exists for unverified data errors to be transmitted to regulators, masquerading as apparent safety signals. Moreover, the flow of sensitive data through third-party platforms introduces significant concerns regarding confidentiality and intellectual property. Both of these issues are, at least in part, resolvable through robust contractual frameworks, and therefore, must be addressed within vendor agreements from the outset.
Access represents another significant consideration. Continuous reporting necessitates infrastructure that large sponsors are considerably better positioned to fund than smaller biotechnology firms. As Parexel CEO Peyton Howell articulated at the RTCT initiative’s launch, "access for biotech sponsors will be critical." For smaller companies, the choice of CRO and technology partner could very well determine whether real-time trials are a viable option for them.
Empowering Procurement: A Seat at the Trial’s Strategic Table
The implementation of flexible CDMO clauses, however well-intentioned, proves ineffective if no one possesses the authority to exercise them swiftly. Key questions regarding who can trigger a scale-up or a pause, based on what evidence, and within what budgetary parameters, must be resolved before the first data signal emerges, not in its wake.
In practical terms, this necessitates category managers having access to the same operational dashboards utilized by study teams. It also calls for joint governance structures involving procurement, clinical supply, and clinical operations. Furthermore, budgeting methodologies must be re-evaluated. Flexible capacity and integration capabilities entail upfront investments. Procurement will be tasked with demonstrating to finance the tangible savings realized through reduced waste and shorter inter-phase durations.
Charting the Course Forward: Actionable Steps for Procurement Leaders
RTCT is an integral component of a broader, nationwide initiative aimed at modernizing US clinical development, including HHS’s Operation TrialBlazer, launched in June 2026. While the formal pilot phase may not dictate the exact pace, the overall direction of travel is unequivocally clear. Procurement leaders can proactively initiate their adaptation process by focusing on three key steps:
- Identify High-Impact Studies: Pinpoint the clinical trials most likely to benefit from and be conducted under real-time reporting protocols. These typically include early-phase oncology studies and other programs where rapid go/no-go decision-making is paramount.
- Embed Flexibility in Contracts: Systematically incorporate flexible capacity terms, real-time data clauses, and clearly defined data access rights into all upcoming contracts with CDMOs, IRT providers, CROs, and patient support vendors.
- Prioritize Real-Time Readiness in Vendor Qualification: Integrate real-time data capabilities and infrastructure readiness as a critical criterion in vendor qualification processes, ensuring the supplier base is prepared before the first RTCT study commences.
RTCT transcends a mere adjustment to the regulatory timeline; it fundamentally redefines the role and purpose of procurement. It shifts from planning around static forecasts to actively managing a supply chain that dynamically adapts to the evolving needs of the trial. The teams that embrace these adaptations now will be the ones best positioned to ensure their trials can progress as rapidly as the emerging evidence allows, ultimately accelerating the delivery of vital medical advancements to patients worldwide.
About the Author
